Table 1.
Baseline characteristics at cancer diagnosis of men with prostate cancer and tumor transcriptome profiling in The Cancer Genome Atlas (TCGA), the Health Professionals Follow-up Study (HPFS), and the Physicians’ Health Study (PHS), by PLZF mRNA expression (low: first quartile; normal: all higher quartiles).
| TCGA | HPFS | PHS | ||||
|---|---|---|---|---|---|---|
| PLZF expressiona | Low | Normal | Low | Normal | Low | Normal |
| n | 84 | 249 | 68 | 186 | 33 | 117 |
| Age, median (range) | 64 (46–74) | 61(43–76) | 65 (47–76) | 66 (49–80) | 65 (55–79) | 66 (51–81) |
| Gleason score in grade | ||||||
| groups, n (%) | ||||||
| 5–6 | 9 (11) | 56 (22) | 4 (6) | 20 (11) | 3 (9) | 30 (26) |
| 3+4 | 30 (36) | 72 (29) | 20 (29) | 71 (38) | 11 (33) | 37 (32) |
| 4+3 | 23 (27) | 55 (22) | 22 (32) | 52 (28) | 10 (30) | 18 (15) |
| 8 | 10 (12) | 35 (14) | 8 (12) | 13 (7) | 5 (15) | 17 (15) |
| 9–10 | 12 (14) | 31 (12) | 14 (21) | 30 (16) | 4 (12) | 15 (13) |
| Clinical stage, n (%) | ||||||
| T1/T2 | 84 (100) | 249 (100) | 56 (85) | 158 (86) | 29 (88) | 107 (93) |
| T3 | 5 (8) | 16 (9) | 3 (9) | 3 (3) | ||
| T4/N1/M1 | 5 (8) | 9 (5) | 1 (3) | 5 (4) | ||
| PSA,b n (%) | ||||||
| <4 | 7 (15) | 12 (9) | 7 (12) | 17 (11) | 5 (19) | 12 (12) |
| 4–10 | 30 (65) | 78 (55) | 27 (47) | 90 (58) | 15 (58) | 64 (62) |
| 10–20 | 7 (15) | 30 (21) | 13 (22) | 30 (19) | 3 (12) | 17 (17) |
| >20 | 2 (4) | 21 (15) | 11 (19) | 17 (11) | 3 (12) | 10 (10) |
| Missing | 38 | 108 | 10 | 32 | 7 | 14 |
| Tissue source, n (%) | ||||||
| Prostatectomy | 84 (100) | 249 (100) | 64 (94) | 172 (92) | 29 (88) | 104 (89) |
| TURPc | 4 (6) | 14 (8) | 4 (12) | 13 (11) | ||
| PLZF copy number | Not available | Not available | ||||
| Gaind | 3 (4) | 16 (6) | ||||
| Diploid | 63 (75) | 215 (86) | ||||
| Heterozygous deletion | 11 (13) | 11 (4) | ||||
| Homozygous deletion | 7 (8) | 7 (3) | ||||
| PTEN status | ||||||
| Intact/Diploid | 43 (51) | 197 (79) | 32 (68) | 97 (82) | 11 (50) | 55 (79) |
| Loss/Any deletion | 41 (49) | 52 (21) | 15 (32) | 21 (18) | 11 (50) | 15 (21) |
a
Categorized as: low, first quartile of mRNA expression; normal, all higher quartiles combined.
b
Serum prostate specific antigen, in ng/ml.
c
Transurethral resection of the prostate. Includes one lymph node sample in a patient from PHS.
d
Includes one amplification event in the mRNA expression category “normal”.